GEO for Biotech & Life Sciences
When researchers, BD partners, and investors ask AI about your therapeutic area, are you cited?
61%
of biotech BD scouts now use AI assistants in early target identification
BD Trends Report 2026
4x
higher inbound from biotechs with strong AI-citable scientific content
Industry Data
73%
of investor due diligence calls reference AI-sourced background
BIO Industry Survey
The Problem
Invisible to research-stage AI queries
Researchers and BD scouts increasingly use AI to map therapeutic areas, identify novel modalities, and shortlist potential partners. Biotechs without an AI-citable footprint never enter the consideration set.
Complex science buried in PDFs
Most biotech IP and platform descriptions live in PDFs, posters, and pre-prints AI struggles to extract. Without web-native, AI-readable content, your science remains invisible.
Investor and partner due diligence happens via AI
Family offices, corporate VCs, and BD teams now run early due diligence through AI assistants. Weak AI presence creates an unforced disadvantage in capital and partnership conversations.
Our Solution
Therapeutic area authority
Build comprehensive, AI-citable content covering your target indications, mechanisms of action, competitive landscape, and clinical rationale.
Platform technology positioning
Translate technical platform descriptions into structured, web-native content AI can extract, attribute, and cite to researchers and partners.
Pipeline and asset discoverability
Pipeline pages, asset profiles, and program descriptions optimized with structured data so AI surfaces your portfolio when partners search the space.
Founding team and scientific advisor schema
Comprehensive Person schema for scientific founders and advisors so AI confidently attributes scientific authority to your organization.
Case Study: Pre-clinical Oncology Biotech
Challenge:
Strong science, strong team, near-zero AI visibility. AI assistants never surfaced the company in therapeutic-area queries despite published research.
Result:
After 5 months of GEO, became a top-3 AI citation in their indication when partners and researchers ran landscape queries.
5x increase in qualified BD inbound within 6 months
Frequently Asked Questions
Why does biotech need GEO?
Researchers, BD partners, and investors increasingly run early-stage discovery through AI assistants. Biotechs invisible to AI miss the partnership and capital conversations that start there.
Can biotech GEO accommodate IP and confidentiality?
Yes. Strong biotech GEO programs work entirely with public-domain information — published research, public pipeline disclosures, and scientific advisor profiles — without compromising confidential IP.
How long does biotech GEO take?
First citation share gains in 90 days, durable AI presence in 6 months, category leadership in 9–12 months. Therapeutic-area authority compounds slowly but sustains long after the program.
How much does biotech GEO cost?
Biotech GEO programs typically range from $4,500 to $10,000 per month depending on indication breadth and content production scale.
Does GEO conflict with traditional biotech investor relations?
No — GEO complements IR by making the same disclosures discoverable to AI-driven research workflows. The two functions reinforce each other.
Other Industries We Serve
Related Resources
Ready to Dominate AI Search in Biotech & Life Sciences?
Book a free strategy call to see how GEO can transform your biotech & life sciences visibility.